Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 12/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937929 | 1.00 | CASP1 (0.56) | CASP1CTRB1CA12CA1CA2 | |
| SCHEMBL6200622 | 1.00 | CASP1 (0.56) | CASP1CTRB1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL6933216 | 0.88 | CTRB1 (0.52) | CASP1CTRB1CA12CA1CA2 | |
| SCHEMBL6201683 | 0.87 | TRPM8 (0.53) | CASP1CTRB1CA12CA1CA2 | |
| SCHEMBL6806205 | 0.86 | HTT (0.56) | CASP1CTRB1CA12CA1CA2 | |
| SCHEMBL14625712 | 0.86 | CTRB1 (0.64) | CTRB1CA12CA1CA2CA9 | |
| SCHEMBL10953605 | 0.86 | CTRB1 (0.64) | CTRB1CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL6538867 | 0.85 | TRPM8 (0.52) | CASP1CTRB1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL6939391 | 0.85 | TRPM8 (0.52) | CASP1CTRB1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL7212603 | 0.85 | TRPM8 (0.52) | CASP1CTRB1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114488-A1 | New processes for producing beta-alanine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| US-6538007-B1 | Hydrates and method of antogonizing glycoprotein IIb/IIIa activity using these compounds is also disclosed. antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114488-A1 | New processes for producing beta-alanine derivatives | BCAT1, BCAT2, AGXT | CASP1 1234/4885CTRB1 77/4885CA12 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.